Our results show that the on/fast-off dynamics of IFNβ signalling are crucial to the response to ICB, which can be therapeutically exploited using antibodies against IFNβ or its receptor IFNAR1, resulting in enhanced tumour clearing. The gene discussed is IFNB1; the disease is neoplasm.